Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors

NCT03576131 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT03576131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2018
Completion date
October 12, 2021
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, triple negative breast cancer, urothelial cancer